As its Carbon Border Adjustment Mechanism (CBAM) enters the final phase on January 1, 2026, the EU has favored the acceleration of carbon regulations...
When it comes to treating obesity, type 2 diabetes, and other chronic health conditions, GLP-1 agonist drugs–such as Ozempic, Zepbound, and Wegovy–have been a...